{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T04:45:50Z","timestamp":1775623550648,"version":"3.50.1"},"reference-count":4,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jaad.2025.12.129","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T06:23:10Z","timestamp":1773728590000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to Woodie et al, \u201cElevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12\/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-\u03b1 inhibitors compared with the general population: A population-based analysis using TriNetX\u201d"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"first","affiliation":[]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[]},{"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[]},{"given":"Peter","family":"van de Kerkhof","sequence":"additional","affiliation":[]},{"given":"Guy S.","family":"Eakin","sequence":"additional","affiliation":[]},{"given":"Kevin","family":"Winthrop","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3480-2661","authenticated-orcid":false,"given":"Joel M.","family":"Gelfand","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2025.12.129_bib1","first-page":"293","article-title":"Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12\/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-alpha inhibitors compared with the general population: a population-based analysis using TriNetX","volume":"94","author":"Woodie","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.129_bib2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jaad.2025.11.033","article-title":"Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with IL-17 or IL-23 inhibitors","volume":"94","author":"Blauvelt","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.129_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jdv.20287","article-title":"Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: recommendations from a SPIN-FRT expert consensus","volume":"39","author":"Torres","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.129_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.5537","article-title":"Core concepts in pharmacoepidemiology: validation of health outcomes of interest within real-world healthcare databases","volume":"32","author":"Weinstein","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226003919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226003919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T03:49:55Z","timestamp":1775620195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226003919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":4,"alternative-id":["S0190962226003919"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.129","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to Woodie et al, \u201cElevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12\/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-\u03b1 inhibitors compared with the general population: A population-based analysis using TriNetX\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.02.123","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}